GlassScriptPhysician profile
Matthew C Neff
NPI 1801030523
$19,176.85
in general payments reported to CMS, 2019-2025
48 companies · $4,731 in 2025
The $4,731 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,116 · 2020: $1,339 · 2021: $2,735 · 2022: $2,704 · 2023: $3,357 · 2024: $3,195 · 2025: $4,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $1,200 · Education: $9.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,073.67 |
| Consulting Fee | $1,200.00 |
| Education | $9.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,339.65 | 2019-2025 | |
| Genzyme Corporation | $1,938.00 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,936.07 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,632.25 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $1,107.23 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Qol Medical, LLC | $724.00 | 2019-2025 | Sucraid |
| Pfizer INC. | $509.40 | 2019-2025 | |
| Celgene Corporation | $474.29 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $362.36 | 2020-2024 | Ocaliva |
| Lilly USA, LLC | $359.80 | 2023-2025 | Omvoh |
| Gilead Sciences, INC. | $348.75 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $335.46 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $323.41 | 2024-2025 | Rezdiffra, Resmetirom |
| Shionogi INC | $277.29 | 2019-2024 | Fetroja |
| Merck Sharp & Dohme LLC | $247.75 | 2019-2024 | Dificid, Delstrigo, Pifeltro |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Neff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.